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ABSTRACT
Chronic inflammation is a well-known risk factor in development of intestinal 
tumorigenesis, although the exact mechanisms underlying development of 
colitis-associated cancer (CAC) still remain obscure. The activity and function of 
immunoproteasome has been extensively analyzed in the context of inflammation 
and infectious diseases. Here, we show that the proteasomal immunosubunit LMP7 
plays an essential role in development of CAC. Mice devoid of LMP7 were resistant to 
chronic inflammation and formation of neoplasia, and developed virtually no tumors 
after AOM/DSS treatment. Our data reveal that LMP7 deficiency resulted in reduced 
expression of pro-tumorigenic chemokines CXCL1, CXCL2 and CXCL3 as well as 
adhesion molecule VCAM-1. As a consequence, an impaired recruitment and activity 
of tumor-infiltrating leukocytes resulting in decreased secretion of cytokines IL-6 and 
TNF-α was observed. Further, the deletion or pharmacological inhibition of LMP7 and 
consequent blockade of NF-κB abrogated the production of IL-17A, which possesses 
a strong carcinogenic activity in the gut. Moreover, in vivo administration of the 
selective LMP7 inhibitor ONX-0914 led to a marked reduction of tumor numbers in 
wild-type (WT) mice. Collectively, we identified the immunoproteasome as a crucial 
mediator of inflammation-driven neoplasia highlighting a novel potential therapeutic 
approach to limit colonic tumorigenesis.
INTRODUCTION
Individuals suffering from inflammatory bowel 
disease (IBD) face a high risk of developing colorectal 
cancer [1]. Environmental and genetic factors play a crucial 
role in the onset of inflammation-driven carcinogenesis 
whereby the loss of function of tumor suppressors such 
as adenomatous polyposis coli (APC) and increased 
activation of β-catenin are mostly accompanied by 
increased expression of pro-tumorigenic cytokines such 
as IL-6, TNF-α and IL-17A. Intestinal epithelial cells 
expressing high levels of TNFR1 are highly sensitive to 
TNF-α, which is able to induce NF-κB-mediated oncogenic 
pathways [2]. Similar to IL-6 and IL-17A, the new member 
of the IL-6 cytokine family, IL-11, profoundly activates 
epithelial STAT3 signalling [3]. Accordingly, in the murine 
experimental model of colitis-associated cancer (CAC), 
both the tumor multiplicity and growth were diminished in 
the absence of IL-17A, IL-6, IL-11 or TNF-α [4]. Taken 
together, the hyperactive intestinal immune system provides 
external factors for intestinal epithelium contributing to its 
constitutive NF-κB and STAT3 activation, which enhances 
the cross-talk of intra-tumoral signaling, resulting in 
excessive proliferation and resistance to apoptosis.
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The constitutive proteasome, which is essential for 
disposal of damaged proteins and maintenance of protein 
turnover in eukaryotic cells, comprises three catalytic 
subunits, β1, β2, and β5. In mammals, the exposure of 
cells to type I and II interferons leads to the formation 
of immunoproteasome that can be distinguished from its 
constitutive homologue through de novo synthesis and 
assembly of the catalytic immunosubunits LMP2 (β1i), 
MECL-1 (β2i), and LMP7 (β5i) [5]. Simultaneously 
with induction of immunoproteasome, IFN-γ upregulates 
the expression of other factors which are needed for 
efficient antigen presentation such as transporter 
associated with antigen processing (TAP) and proteasome 
activator 28 (PA28) [6]. The primary function of 
immunoproteasome has been connected to the optimal 
generation of peptides for MHC class I presentation 
[7]. Recent reports have revealed other important roles 
of immunoproteasomes in immune system. During 
inflammation, immunoproteasomes help constitutive 
proteasomes to handle the enhanced pool of proteasomal 
substrates preventing aggregate formation of damaged 
proteins in the cells [8]. Importantly, we and others have 
shown in mouse models of colitis and rheumatoid arthritis 
that immunoproteasomes were essential for initiation of 
inflammatory processes [9–11].
With regard to the activation of classical NF-κB 
signalling pathway, contradictory data have been published 
in earlier reports. While some researcher groups do not 
see any impairment of NF-κB activity in the absence of 
intact immunoproteasome, we and others have observed 
defective NF-κB activation in mice devoid of LMP7 or 
LMP2 [10, 12, 13]. Given the broad functional aspects 
of its activities in immune cells, we hypothesised that the 
immunoproteasome might be a crucial factor involved in 
the onset of inflammation-driven carcinogenesis.
RESULTS
Reduction of colitis-associated carcinogenesis in 
the absence of LMP7
The immunoproteasome is crucial for the 
optimization of CD8+ T cell-mediated immune responses 
during viral or bacterial infections [14]. Novel data have 
demonstrated that immunoproteasomes also efficiently 
control the proinflammatory activity of immune cells [10, 
13]. In contrast to lymphoid tissues with high expression of 
immunoproteasomes, the colonic lamina propria exhibits 
low amounts of this enzymatic complex [15]. Particularly, 
the expression of LMP2 and LMP7 is much lower 
than that of their counterparts β1 and β5, respectively 
(Supplementary Figure S1), which might be one important 
mechanism to protect the host from immune overreaction 
to commensal antigens. Previously, we and others have 
shown that the mice devoid of intact immunoproteasomes 
display reduced colonic inflammation and tissue 
destruction [9, 11]. During the induction of colitis, we 
observed increased expression of immunoproteasome 
subunits LMP2 and LMP7 in the inflamed colon of 
DSS-treated WT mice (Figure 1A and 1B). Recently, we 
reported an up-regulation of proteasome quantity in WT 
but not in LMP7 deficient mice infected with Listeria 
monocytogenes [16]. Comparable to this finding, we 
detected a significant increase in the expression of α4 
subunit, which is a structural part of both constitutive and 
immunproteasomes, on day 8 after induction of colitis 
by dextran sodium sulfate (DSS) in WT mice. On the 
contrary, no up-regulation of this proteasomal subunit 
was observed in DSS-treated lmp7−/− animals. Moreover, 
by using a pan-20S proteasome antibody, an increase of 
about 25 % of total amount of 20S proteasomes was found 
in WT mice after exposure to DSS for 8 and 12 days. 
However, no increase in overall abundance of mature 
20S proteasome was seen in lmp7−/− mice during colonic 
inflammation (Figure 1C and 1D). Thus, it seems that 
LMP7 deficient mice are unable to efficiently upregulate 
expression and assembly of proteasomal proteins in 
response to ongoing colonic inflammation.
We speculated that the lower proteasome quantity 
observed in animals devoid of LMP7 might also 
influence the development of colitis-associated cancer 
(CAC). To investigate the role of immunoproteasomes in 
development of inflammation-driven carcinogenesis, WT 
and lmp7−/− mice were treated with azoxymethane (AOM)/
DSS and induction of colitis-associated neoplasia in colon 
was monitored for 80 days. During the course of AOM 
treatment and cyclic administration of DSS in drinking 
water, a profound body weight loss accompanied with 
occurrence of multiple tumors was observed in WT mice, 
whereas less significant loss of body weight, no visible 
adenocarcinomatous lesions and no loss of mucous-
producing goblet cells were detectable in H&E or PAS-
stained colonic tissue sections of LMP7 deficient animals 
(Figure 2A-2C). Overall, these data suggest that the 
inflammatory responses driven by immunoproteasomes 
are involved in colonic tumorigenesis.
The decrease in proteasome amount and altered 
catalytic activity in the absence of LMP7 might have a 
significant impact on many cellular signalling cascades. 
The involvement of transcription factor NF-κB in both 
inflammatory cells and colonic epithelium has been shown 
to play a crucial role in colitis-associated tumorigenesis [3, 
17–19]. Our previous analysis has clearly shown that the 
activation of canonical NF-κB pathways was significantly 
impaired in the absence of immunoproteasomal subunits 
[13]. Following the exposure of colonic cells to pathogen-
associated molecular patterns (PAMPs) and pro-
inflammatory cytokines due to the damage caused by DSS, 
the proteasomes in colonic epithelial and immune cells 
rapidly process NF-κB precursor protein p105 and degrade 
IκBα. In accordance with decreased total proteasome 
abundance in LMP7 deficient cells, we observed strong 
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reduction in the expression of NF-κB proteins detected 
by lower p105, p50, p65 and c-Rel levels in the colon of 
LMP7 deficient animals as compared to WT mice 80 days 
after initiation of CAC (Figure 2D-2F).
The impaired recruitment of tumor-associated 
leukocytes into the colon of LMP7 deficient mice
An inflammatory environment promotes cancer 
development by providing newly emerging tumors with 
factors essential for their growth, angiogenesis and 
metastasis. Novel data have identified TNF-α, IL-17A and 
IL-6 as crucial link between enhanced activity of immune 
system and colon carcinogenesis [20]. To explore the 
relevance of immunoproteasome in the regulation of pro-
tumorigenic cytokines, we measured inflammation-driven 
TNF-α and IL-6 secretion after initiation of AOM/DSS 
treatment. Colonic explants of AOM/DSS-treated LMP7 
deficient mice secreted almost negligible amounts of these 
cytokines as compared to strong production in colon of 
WT animals (Figure 3A). Colitis and carcinogenesis are 
intimately linked by enhanced activity of infiltrating 
immune cells and increased secretion of chemokines and 
cytokines. Recently, it has been shown that recruitment of 
neutrophils to the inflamed colon favours development of 
inflammation-driven tumorigenesis [21, 22]. Furthermore, 
the genes encoding chemokines, namely Cxcl1 and 
Cxcl2, which are responsible for recruitment of CXCR2+ 
blood neutrophils, are strongly up-regulated in colonic 
adenocarcinomatous lesions [23]. Accordingly, blocking 
CXCR2 or CXCL1 profoundly suppressed intestinal 
inflammation-driven carcinogenesis [23, 24]. On day 
30 after induction of CAC, we detected a significantly 
reduced influx of neutrophils in the colon of lmp7−/− 
mice in comparison to WT animals (Figure 3B and 3C). 
Moreover, the relative mRNA expression of Cxcl1, Cxcl2 
and Cxcl3 as well as that of their receptors Cxcr1 and 
Cxcr2 was significantly reduced in the colon of AOM/
DSS-treated LMP7 deficient mice as compared to WT 
mice (Figure 3D and 3E). The migration of neutrophils 
into the peritoneal cavity during induction of peritonitis 
has been described to be mediated via CXCL1 and CXCL2 
[25]. To test if observed defective expression of Cxcl1 
and Cxcl2 in lmp7−/− mice has an impact on recruitment 
Figure 1: Abundance of proteasomal subunits after treatment of WT mice with DSS. A. Immunoblot analysis for LMP7 
and LMP2 in naïve and DSS-treated mice (day 8 after induction of colitis). β-Actin served as a loading control. A representative of two 
independent experiments is shown. B. Densitometric quantification of immunoblot analyses for LMP2 and LMP7 expression on day 8 after 
DSS treatment of WT mice. C and D. Densitometric analysis for protein expression of structural proteasomal subunit α4 and for all pan-20S 
subunits (MP3 Ab) on indicated days after exposure to 3% DSS. The membranes were stained against GAPDH as loading control. Data 
represent mean ± SEM. Three independent experiments were performed.
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of inflammatory cells during peritonitis, we measured the 
percentage of neutrophils in peritoneal lavages 4 h after 
intraperitoneal injection of thioglycollate. Similar to the 
detected migratory defects in intestine, the absence of 
LMP7 significantly reduced the influx of neutrophils in 
the peritoneum (Supplementary Figure S2).
Transmigration of neutrophils through endothelial 
cells is mediated via activation of specific adhesion 
receptors such as vascular cell adhesion molecule-1 
(VCAM-1). In contrast to WT counterparts, almost 
no up-regulation of this molecule during induction 
of CAC in the colon of lmp7−/− mice was detected, 
which suggests that several mechanisms contribute to 
observed migratory defects (Figure 3F). Previously, it 
was shown that TNF-α-triggered VCAM-1 expression in 
endothelial cells is under transcriptional control of NF-
κB and that the blockade of NF-κB activity by unspecific 
proteasome inhibitor MG132 was able to suppress the 
expression of VCAM-1 and in vitro transmigration of 
neutrophils [26, 27]. To examine if VCAM1 expression 
is directly regulated by LMP7, we stimulated human 
umbilical vein endothelial cells (HUVECs) with TNF-α 
in the presence or absence of specific LMP7 inhibitor 
ONX-0914. These data revealed that the inhibition of 
the immunoproteasome subunit LMP7 downregulates 
VCAM1 gene expression in endothelial cells (Figure 3G). 
Importantly, the expression of Cxcl1, Cxcl2 and Cxcl3 
is also transcriptionally regulated by canonical NF-κB 
signaling pathway [28]. For Cxcl1, Cxcl2, Cxcl3 and 
VCAM1, we were able to find several NF-κB binding 
sequences in proximal promoter regions of humans, 
rats and mice. Particularly, the regulatory region 100-
200 base pairs upstream of transcription start site (TSS) 
comprised the typical NF-κB binding motif with highly 
conserved sequence in all examined genes and species 
(Supplementary Table S1). Therefore, we concluded that, 
in lmp7−/− mice, the reduced NF-κB activity might be 
responsible for impaired expression of VCAM1, Cxcl1, 
Cxcl2 and Cxcl3. Further, we analysed immune cell 
populations that play an anti- or pro-tumorigenic role 
in development of CAC. While Foxp3+ Tregs and CD8+ 
T cells were comparable in WT and LMP7 deficient 
animals after AOM/DSS treatment, a moderate defect 
in macrophage cell numbers was detected in the colonic 
lamina propria of LMP7 deficient mice (Figure 3H-3J). 
Taken together, during the inflammation-associated-
carcinogenesis, the immunoproteasome subunit LMP7 
is crucially involved in the regulation of expression of 
pro-tumorigenic chemokines, cytokines and adhesion 
molecules.
Figure 2: Immunoproteasome subunit LMP7 is essential for development of colitis-associated cancer (CAC). A. CAC 
was induced in WT and lmp7−/− mice and the change in weight was monitored in naïve and AOM/DSS-treated mice over a period of 75 days. 
Data represent mean ± SEM (n=10-12 mice per group). ***P<0.001. B. Representative images of H&E- and PAS-stained colon sections of 
control or AOM/DSS-treated mice (day 80). Scale bars: 100µm for H&E and 200µm for PAS staining. C. Colonic tumor incidence in naïve 
and AOM/DSS treated mice (day 80). Data represent mean ± SEM (n=10-12 mice per group). ***P<0.001. D and E. Reduced NF-κB levels 
in LMP7 deficient mice after induction of CAC. Immunoblot analysis for p105/p50 (D), p65 and c-Rel (E) was performed for the whole 
colonic tissue of AOM/DSS-treated mice (day 80). α-Tubulin or β-Actin served as a loading control. A representative of two experiments 
is shown. F. Densitometric analysis for colonic p65 expression on day 80 after induction of CAC in WT and lmp7−/− mice. Data represent 
mean ± SEM of two independent experiments and are normalized to p65 expression in the colon of naïve WT mice. **P<0.01.
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Colonic IL-17A production is reduced in 
LMP7 deficient mice during colitis-associated 
carcinogenesis
In an experimental CAC model, IL-17A deficient 
mice have been shown to exhibit significantly lower 
tumor numbers compared to WT mice [29]. A recent 
study has demonstrated a redundant role for adaptive 
and innate sources of IL-17A production during the 
colonic carcinogenesis indicating the need for therapeutic 
targeting of cytokine itself rather than cellular origin of 
IL-17A [30]. During the development of colitis or CAC, 
we observed a significantly reduced secretion of IL-17A in 
the colon of lmp7−/− and rag1−/−lmp7−/− mice as compared 
to WT and rag1−/− control animals, respectively (Figure 4A 
and 4B). These data suggest that the enzymatic activity of 
LMP7 regulates IL-17A production not only in Th17 cells 
but also in innate lymphoid cells, and possibly in other 
cell types. Interestingly, during intestinal inflammation, 
a very similar phenotype was observed between lmp7−/− 
and il17af−/− mice, which displayed less weight loss, lower 
frequencies of neutrophils and decreased colonic secretion 
of TNF-α as compared to WT mice (Figure 4C-4E).
Previously, it has been published that the blockade 
of LMP7 activity by its selective inhibitor ONX-0914 
reduced expression of IFN-γ and IL-17A by Th1 and 
Th17 cells and increased Foxp3 expression by Tregs, 
respectively [31]. To determine whether lmp7−/− and 
lmp2−/− T cells exhibit defective effector functions, 
we isolated CD4+ T cells from WT animals and mice 
deficient for LMP2 or LMP7 and cultivated them 
for three days under Th1-, Th17- and Treg-inducing 
conditions. In contrast to previous study, we were able 
to observe only selective defect under Th17-polarizing 
conditions. There were no significant differences in 
frequencies of IFN-γ+ Th1 cells or Foxp3+Tregs between 
Figure 3: Regulation of neutrophil-recruiting chemokines and VCAM-1 by LMP7 during progression of CAC. 
A. Secretion of TNF-α and IL-6 by ex vivo colon explants of naïve or AOM/DSS-treated mice at day 30 after induction of CAC was 
measured by ELISA. Data represent mean ± SEM (n = 10-12 mice per group). B and C. Leukocytes were isolated from the colon of naïve 
and AOM/DSS-treated mice on day 30 after CAC induction. Cells were stained and gated on SSChigh granulocyte gate. Frequency (B) 
and total cell numbers (C) of CD11b+Ly-6G+ neutrophils were analysed by flow cytometry. D-F. Quantitative real-time PCR analyses for 
expression of Cxcr1, Cxcr2 (D) Cxcl1, Cxcl2, Cxcl3 (E) and VCAM1 (F) was performed using colon tissues from naïve and AOM/DSS-
treated mice at day 30 after CAC induction. G. VCAM1 expression in HUVECs treated with TNF-α (10 ng/ml) in the presence or absence 
of ONX-0914 (100 nM). Pooled data from two independent experiments are shown. H. Absolute cell numbers of colonic MHC-II+ CD11b+ 
macrophages on day 30 after CAC induction. I. Colonic Treg frequencies on day 30 after AOM/DSS treatment of WT and LMP7 deficient 
mice. J. Cell numbers of CD8+ T cells in colon of WT and LMP7 deficient mice on day 30 after CAC induction. For the analyses (C-F 
and H-J), data represent mean ± SEM (n =10-12 mice per group). For all experimental analyses: n.d., not detectable, n.s., not significant, 
*P<0.05, **P<0.01, ***P<0.001.
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WT, LMP2 and LMP7 deficient mice. In contrast, IL-17A 
expression was impaired in lmp7−/− and lmp2−/− Th17 
cells as compared to WT counterparts suggesting a 
direct role for immunoproteasomes in controlling 
production of this pro-tumorigenic cytokine (Figure 5A 
and 5B, and Supplementary Figure S3). Similarly, we 
were not able to detect defective IFN-γ expression and 
Th1 differentiation after treatment of WT CD4+ T cells 
with ONX-0914. In contrary, we even observed a slight 
increase in production of IFN-γ upon LMP7 blockade 
(Figure 5C and 5D). Finally, Th17 cells treated with 
a specific NF-κB inhibitor BAY 11-7082 or LMP7 
inhibitor ONX-0914 showed defective expression of IL-
17A compared with untreated Th17 cells (Figure 5E). We 
and others have recently shown that NF-κB signalling 
regulates the induction of IRF4 in the lymphocytes, 
Figure 4: Deletion of LMP7 leads to reduction of IL-17A production. A. Secretion of IL-17A by ex vivo colon explants of 
naïve or AOM/DSS-treated mice at day 30 after induction of CAC was measured by ELISA. Data represent mean ± SEM (n = 10-12 mice 
per group). B. IL-17A secretion in overnight colon cultures at day 8 after exposure of rag1−/− and rag1−/−lmp7−/− mice to 2.5 % DSS. Data 
represent mean ± SEM (n = 8 mice per group). C. Total numbers of colonic CD11b+Ly-6G+ neutrophils at day 6 after induction of colitis 
was analysed by flow cytometry. D. Secretion of TNF-α in overnight colon cultures at day 6 after exposure of WT and il17af−/− mice to 2.5 
% DSS. E. Monitoring of weight loss in il17af−/− mice after oral treatment with 2.5 % DSS for 5 days. For (C-E), data represent mean ± 
SEM (n =8 mice per group), **P<0.01, ***P<0.001.
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which is required for IL-17A production by Th17 cells 
[32–34]. Following the T cell receptor (TCR) activation, 
the IKK-induced p105 degradation by proteasome is 
needed to release the associated NF-κB subunits to 
translocate into the nucleus and modulate the gene 
expression. Here, we demonstrate that ONX-0914-treated 
Th17 cells were not capable of activating NF-κB p105 
signalling pathway and of inducing IRF4 expression, 
whereas the phosphorylation of ERK was not affected 
(Figure 5F-5H). Similarly, IRF4 levels were reduced 
in Th17 cells treated with BAY 11-7082 as compared 
with untreated Th17 cells (Figure 5H). These results 
indicate non-redundant role of LMP7/NF-κB/IRF4 axis 
in regulation the expression of IL-17A by Th17 cells.
Selective inhibition of LMP7 suppresses 
inflammation-driven colon cancer
The LMP7 inhibitor ONX-0914 has been shown to 
attenuate the progression of inflammation in experimental 
models of arthritis and colitis [9, 10]. As the VCAM1 
gene expression and IL-17A production was also down-
regulated after the treatment of cells with ONX-0914, we 
hypothesised that proteosomal immunosubunits might be 
a specific target for development of anti-inflammatory 
therapies needed for dampening the ongoing inflammation-
driven cancer. A recent study has described high selectivity 
of ONX-0914 for LMP7 both in vitro and in vivo, however, 
the treatment of mice with higher doses of this inhibitor 
Figure 5: Specific blockade of LMP7 reduces Th17- but not Th1-mediated immune responses. A. Representative dot 
plots showing the expression of IL-17A and IFN-γ in purified CD4+ T cells cultured under Th17 conditions for three days. Three similar 
experiments were performed. B. CD4+ T cells were purified from WT, lmp7−/− and lmp2−/− mice and cultured under Th17-, Th1- and Treg-
inducing conditions for three days, respectively. Three similar experiments were performed. Data are shown as mean ± SEM. **P<0.01, 
***P<0.001. C and D. CD4+ T cells were purified from spleens and lymph nodes of WT mice and cultured with or without ONX-0914 
(250 nM) under Th1-inducing conditions. Representative dot plots show the expression of IFN-γ and IL-17A (C). Data from two similar 
experiments (D) are displayed as mean ± SEM. *P<0.05. E. Representative FACS dot plots showing the IL-17A and IFN-γ expression 
in CD4+ T cells cultured under Th17 conditions for three days in the presence of inhibitors BAY 11-7082 and ONX-0914 (both 300 nM), 
respectively. Three experiments were performed. F. Analysis of NF-κB and ERK activation in CD4+ T cells after stimulation with PMA/
ionomycin for indicated times. One group of cells was additionally treated with ONX-0914 (400 nM). Two similar experiments were 
performed. G. Immunoblot analysis of IRF4 expression in Th17 cells cultured for 16 h in the presence of ONX-0914. H. Th17 cells were 
cultured for three days with or without BAY 11-7082 and ONX-0914 (both 300 nM) and subsequently intracellular staining for IRF4 was 
performed. Three similar experiments were performed.
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was shown to be very toxic and even lethal [10]. We tested 
the dose-dependent toxicity of ONX-0914 and found that 
administration of 6 mg ONX-0914 per kg mice at every 
second day starting at day 5 after induction of CAC was 
well tolerated and had a significant impact on the course 
of carcinogenesis. The treatment of WT mice with ONX-
0914 led to less pronounced shortening of colon length 
and reduced production of pro-tumorigenic cytokines 
TNF-α and IL-17A in the colon after administering 
AOM and DSS or DSS alone (Figure 6A-6C). Although 
some hyper-proliferation of colonic epithelial cells was 
observed after ONX-0914 administration, mice treated 
with this inhibitor had markedly reduced tumor numbers 
and size in comparison to normal WT animals as shown 
in representative H&E sections, macroscopic tumor count 
and microscopic tumor progression score (Figure 6D 
and 6E).
In summary, our data identify immunoproteasome as 
a crucial factor contributing to initiation and progression 
of inflammation-driven tumorigenesis. Our novel findings 
show that secretion of pro-tumorigenic cytokines such 
as IL-17A as well as of chemokines is controlled by 
immunoproteasome subunit LMP7. The LMP7-dependent 
up-regulation of CXCL1, CXCL2, CXCL3 and VCAM-1 
expression leads to alternations in the microenvironment 
of tumors and progression of colorectal carcinogenesis 
(Figure 6F). Given that colon cancers often arise 
from chronic inflammation and selective inhibition of 
immunoproteasome subunit LMP7 results in decreased 
production of pro-inflammatory and pro-tumorigenic 
molecules, this study provides a therapeutic rationale for 
targeting immunoproteasomes in colorectal carcinogenesis 
associated with colitis.
DISCUSSION
Diverse cellular functions of proteasomes have been 
described, whereby the regulation of cell cycle, apoptosis, 
cellular proliferation and activation of transcription of 
various genes are closely connected to development of 
cancer [35]. The ubiquitin-proteasome system (UPS) is 
considered as a promising target for cancer therapy and 
some proteasome inhibitors such as bortezomib are already 
implemented in the treatment of malignant diseases [36]. 
Mice with a targeted deletion of the immunoproteasome 
subunit LMP7 had originally been described to have 
reduced levels of MHC class I cell surface expression 
[37], which might lead to the conclusion that cancer 
immunosurveillance and CTL-mediated antitumor 
immunity might be impaired in these animals. On the 
contrary, given the crucial role of immunoproteasomes 
in regulation of various pro-inflammatory mediators, one 
might also speculate on a potential pro-carcinogenic role 
for immunoproteasomes during the progression of chronic 
inflammation. In accordance, we found that genetic 
ablation or therapeutic inhibition of LMP7 reduced pro-
inflammatory responses and subsequent CAC development 
in the AOM/DSS model of carcinogenesis.
Chronic inflammation appears to be one of the 
most frequent risk factors for development of intestinal 
tumor growth and progression to malignancy [4]. 
Recent studies have highlighted the mechanisms by 
which the cytokines secreted by inflammatory cells and 
regulated by the transcription factor NF-κB such as 
TNF-α, IL-6 and IL-17A stimulate tumor development 
and progression [20]. Although NF-κB is constitutively 
activated in many tumors, mutations in the family of 
NF-κB transcription factors are very rare. Thus, during 
the colon carcinogenesis, the pro-tumorigenic function 
of NF-κB might originate from mutations in regulatory 
molecules in inflammatory cells acting upstream of this 
transcription factor. In the mouse model of CAC, the 
intense NF-κB-mediated interaction between tumors and 
infiltrating immune cells is reflected in the observation that 
myeloid-specific deletion of NF-κB reduces tumor burden 
in mice [38].
Our novel data demonstrate that the 
immunoproteasome subunit LMP7 is crucially involved 
in exaggerated colonic inflammatory reactions that favour 
development of intestinal carcinogenesis. In the AOM/
DSS model of colon carcinogenesis, we observed reduced 
NF-κB activity and significantly less tumors in LMP7 
deficient mice as compared to WT animals. The previous 
studies investigating kinetics of IκBα degradation and NF-
κB activation pointed to the dysregulated NF-κB signaling 
pathway in the absence of LMP7 and LMP2 [8, 12, 39]. 
The observed delay in the nuclear translocation of active 
NF-κB subunits might be explained by altered catalytic 
specificity and decreased total proteasome amount in the 
absence of immunoproteasomes. These defects highlight 
an essential function for immunoproteasomes in immune 
cells apart from their role in processing of MHC class I 
antigens.
Our result indicate that the immunoproteasome 
function was associated with a variety of inflammatory 
processes in the gut such as recruitment of neutrophils 
and regulation of expression of chemokines, cytokines 
and adhesion molecules. Interestingly, we observed a 
defective production of IL-17A in innate and adaptive 
immune cell compartments in the absence of LMP7. 
This is consistent with novel data suggesting that both 
innate and adaptive cellular sources of IL-17A contribute 
to progression of colon carcinogenesis [30]. It seems 
that pro-tumorigenic Th17 cells are crucially dependent 
on ubiquitin-proteasome pathway and especially on the 
expression of LMP7 to activate NF-κB/IRF4 axis needed 
for intact production of IL-17A.
Recently, efforts have been made to develop 
immunoproteasome-specific inhibitors since many 
unspecific proteasome inhibitors are associated with 
unwanted and toxic effects in spite of their promising 
therapeutic applications. A number of immunoproteasome-
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Figure 6: Specific blockade of LMP7 inhibits development of CAC. A. Scheme for the experimental course for induction of CAC 
in WT mice using 8 mg/kg AOM and 3 cycles of DSS (2.5%). Mice were treated with 6 mg/kg ONX-0914 three times per week starting at day 
5 after AOM administration. B. Colon length of DSS-treated WT mice with or without ONX-0914 (6 mg/kg mice, i.p. administration daily) 
was measured at day 8 after colitis induction (n=6 mice per group). Data represent mean ± SEM, **P<0.01, n.s., not significant. C. Cytokine 
secretion by colon ex vivo explants of AOM/DSS treated WT mice in the presence or absence of ONX-0914 was measured by ELISA at day 30 
after CAC induction. *P<0.05. D. Colonic tumor score in naïve and AOM/DSS-treated WT mice with or without ONX-0914 administration 
(day 80 after CAC induction). For (C and D), data represent mean ± SEM and are representative of two independent experiments (n =10-12 
mice per group), n.d., not detectable, ***P<0.001. E. Representative images of H&E-stained colon sections of naïve and AOM/DSS-treated 
WT mice injected with ONX-0914 as described in (A). Histology analysis was performed at day 80 after CAC induction. Scale bar: 100µm. 
F. Schematic overview showing the role of LMP7 in development of CAC. In inflamed colon, the increased expression of immunoproteasome 
subunit LMP7 leads to NF-κB/IRF4-mediated secretion of IL-17A which impacts the recruitment of neutrophils into the colon and promotes 
carcinogenesis. Additionally, LMP7/NF-κB axis regulates the expression of chemokines CXCL1-3 and adhesion molecule VCAM-1. The 
inhibition of LMP7 with ONX-0914 affects the tumor formation by dampening the pro-inflammatory mediators.
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specific inhibitors are currently being tested in pre-
clinical and clinical studies and among them ONX-0914 
has been proven as a potent agent to treat inflammatory 
disorders such as colitis and rheumatoid arthritis [10, 
31]. This inhibitor has been shown to be 20- to 40-fold 
more selective for LMP7 subunit over its constitutive 
counterpart β5 [10]. Notably, the treatment of WT mice 
with ONX-0914 reduced expression of pro-tumorigenic 
cytokines and results in significantly attenuated symptoms 
of experimental CAC. Moreover, LMP7 blockade by 
ONX-0914 was associated with impaired expression of 
pro-tumorigenic cytokine IL-17A and adhesion molecule 
VCAM-1 in vitro. Although we did not observe reduced 
frequency of intestinal CD8+ T cells in AOM/DSS 
treated mice lacking LMP7, a treatment with LMP7 
inhibitor might have some undesired side effects such as 
increased susceptibility to certain infections and altered 
antigen processing of tumor neoantigens. Together, these 
observations identify immunoproteasome, in particular 
its subunit LMP7, as a potential therapeutic target for 
treatment of colon carcinogenesis.
MATERIALS AND METHODS
Mice
C57BL/6 WT mice were purchased from Charles 
River Laboratory. lmp7−/−, lmp2−/−, il17af−/−, rag1−/− and 
rag1−/− lmp7−/− mice (on C57BL/6 background) were bred 
at the animal facility of the Biomedical Research Center, 
University of Marburg. il17af−/− mice were obtained from 
Immo Prinz, Institute of Immunology, Hannover Medical 
School, Hannover, Germany.
Tumor and colitis induction
Sex-matched mice were injected with AOM (Sigma-
Aldrich) intraperitoneally (i.p.) at a dose of 8 mg/kg body 
weight. After 5 days, mice were treated with 2.5% DSS (MP 
Biomedicals) administered via drinking water for 5 days, 
followed by 14 days of normal drinking water. The DSS 
cycle was repeated twice as indicated. Mice were sacrificed 
on day 80 for analyses. In some experiments, acute colitis 
was induced by treating mice orally with 2.5 % DSS and 
analysis was performed on day 6 or day 8 after induction of 
colitis. In some experiments, WT mice were treated with 6 
mg/kg of LMP7 inhibitor ONX-0914 (i.p., three times per 
week) starting at day 5 after AOM administration.
Histology
Colon tissue cryosections were stained with 
hematoxylin and eosin (H&E) and periodic acid-Schiff 
(PAS). Slides were examined blindly by two investigators 
with bright field microscopy. Digital images were taken 
using Leica DFC480 camera and Leica Application Suite 
V3.8 software.
Isolation of colonic lamina propria mononuclear 
cells (LPMCs)
Colon pieces were shaken for 30 min at 37°C at 150 
rpm in RPMI medium supplemented with 10% FCS, 1 mM 
L-glutamine and Penicillin/Streptomycin. The epithelial 
cell fraction was released by vortexing vigorously in PBS 
(2 % FCS). The remaining colon tissue was digested with 
0.4 mg ml-1 collagenase D (Roche) and collagenase VIII 
(Sigma) with constant shaking at 150 rpm for 45 min at 
37°C. The cell suspension were washed and resuspended 
in 40% percoll (Merck). Cells were carefully layered on 
70% percoll. After centrifugation at 2000 rpm for 30 min, 
the LPMCs were collected from the interphase, washed 
and resuspended in 1ml colon medium. LPMCs were 
stained with anti-CD11b (clone M1/70, eBioscience), 
anti-Ly-6G (clone 1A8, BioLegend), anti-CD4 (clone 
RM4-5, BioLegend), anti-CD8 (clone 53-6.7) and anti-
MHC II (clone TIB120, purified at Max-Planck-Institute). 
Foxp3-expressing Tregs were detected by using the Foxp3 
staining kit (clone FJK-16s, eBioscience). Flow cytometry 
was performed on a FACSCalibur flow cytometer (Becton 
Dickinson) and the data was analysed using FlowJo 7.6 
(Tree Star).
Colon ex vivo explant culture and ELISA
1 cm sections of the proximal colon were washed 
with PBS to remove feces, and then cut longitudinally. The 
colon sections were incubated in 1 ml of RPMI medium 
supplemented with 10% FCS (Sigma) and Penicillin/
Streptomycin (PAA). The sections were cultured at 
37 °C, 5% CO
2
. Supernatants were harvested after 24 
h and cytokine concentrations were determined by 
ELISA. TNF-α, IL-17A and IL-6 ELISA were performed 
according to manufacturer’s instructions using OptEIA 
ELISA kits (BD Bioscience).
Western blot
Using a homogenizer (Ultra-Turrax IKA), pieces 
of whole colon tissues were lysed in cold RIPA lysis 
buffer (Sigma) containing protease inhibitors (Thermo 
Scientific), Na
3
VO
4
 (0.2 mM), NaF (20 mM) with 
incubation on ice for 15 min and intermittent vortexing. 
Total protein quantification of the samples was performed 
with BCA assay kit (Pierce). 20 μg aliquots of protein 
were separated by electrophoresis in 12% SDS PAGE gels 
(Bio-Rad) followed by transfer onto a PVDF membrane 
(Roche). Membranes were blocked for 1 hour, followed 
by incubating the membrane with primary antibody. 
Following primary antibodies were used: anti-p65 (Santa 
Cruz Biotechnology), anti-p105/p50 (eBioscience), anti-
LMP7 and anti-LMP2 (Cell Signaling and Santa Cruz 
Biotechnology, respectively), anti-p-ERK (Cell Signaling) 
and anti-IRF4 (Santa Cruz Biotechnology). The analysed 
proteins were detected by chemiluminescence (Biostep) 
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using ImmunoCruz (Santa Cruz Biotechnology). For 
detection of 20S proteasome subunits, the quantitative 
two-colour fluorescent immunoblot analysis was 
performed as described previously [16].
CD4+ T cell differentiation
CD4+ T cells from WT, lmp7−/− or lmp2−/− mice 
were isolated from spleen and lymph nodes by negative 
magnetic cell sorting (MACS, Miltenyi Biotec). CD4+ 
T cells were cultured containing plate-bound 5 μg/ml 
anti-CD3 (clone 145-2C11) and 1 μg/ml soluble anti-
CD28 (clone 37.51). For Th17 differentiation, cultures 
were supplemented with 5 μg/ml α-IFN-γ (clone 
XMG1.2), α-IL-4 (10% culture supernatants of clone 
11B11), 50 U/ml rhIL-2 (Novartis), 1ng/ml rhTGF-β1 
(PeproTech) and 40 ng/ml IL-6 (PeproTech). 200-400 
nM ONX-0914 (Onyx Pharmaceuticals) or 300-400 
nM BAY 11-7082 (Sigma-Aldrich) were added to the 
Th17 differentiation medium for indicated time points. 
Cells were restimulated with 750 ng/ml of ionomycin, 
50 ng/ml of PMA in presence of 10 µg/ml Brefeldin A 
(all three substances, Sigma-Aldrich) and were analysed 
for IL-17A (clone eBio17B7, eBioscience) and IFN-γ 
(clone XMG1-2, eBioscience) production by intracellular 
staining (ICS). In some experiments, expression of 
transcription factor IRF4 (clone 3E4, eBioscience) was 
analysed by ICS.
Cell line experiments
Human umbilical vein endothelial cells (HUVECs) 
(PromoCell) were cultured in endothelial cell growth 
medium (PromoCell) at 37 °C, 5% CO
2
 in 75 cm2 tissue 
culture flasks. HUVECs from passage 3 to 5 were used 
for experiments. 1 x 105 cells were seeded in 6-well plates 
and were allowed to adhere overnight. Cells in the control 
group were left untreated. For stimulation experiments, 
HUVECs were pretreated with or without 100 nM ONX-
0914 (Onyx Pharmaceuticals) for 2 h. Both untreated and 
ONX-0914 treated cells were then further stimulated with 
10 ng/ml recombinant human TNF-α (PeproTech) and 
then harvested after 6 h.
Quantitative real-time PCR
Using TRI Reagent (Sigma-Aldrich), the colon 
tissues were homogenized and total RNA was extracted 
according to manufacturer’s instructions. RevertAid First 
Strand cDNASynthesis Kit (Thermo Scientific) was used 
to generate complementary DNA (cDNA) according to 
the manufacturer’s instructions. Quantitative real-time 
PCR was conducted on a StepOne Plus device (Applied 
Biosystems). Quantification of cDNA was carried out by 
normalization to expression of housekeeping genes HPRT-
1 or GAPDH using the ΔΔCt method. The primers used 
for q RT-PCR are listed in Supplementary Table S2.
Statistics
Data are presented as mean ± SEM and were 
analyzed with GraphPad Prism (GraphPad Software). 
Statistical analyses was done by either Student t-test or 
1-way ANOVA.
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